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Abstract
Background: The multidisciplinary tumour conference (MTC) represents the standard of care in the
management of hepatocellular carcinoma (HCC). Clinical outcomes in relation to adherence and non-
adherence to MTC recommendations have not been studied.
Methods: A total of 137 patients with HCC and cirrhosis whose cases were submitted to a first MTC
discussion between 1 January 2009 and 31 December 2010 were identified. Clinical data, management
recommendations, adherence, treatment regimens and overall survival were reviewed.
Results: There were 419 MTC discussions on 137 patients with cirrhosis and HCC. The MTC recom-
mendations made in 145 discussions on 90 separate patients were not followed. Patient-related reasons
for deviation from MTC recommendations included failure to attend for follow-up (n = 24, 16.6%), clinical
deterioration (n = 19, 13.1%) and patient preference (n = 13, 9.0%). Physician-related reasons for
discordance included treating physician preference (n = 43, 29.7%) and finding that the patient was not
a candidate for the recommended intervention (n = 37, 25.5%). After the first MTC discussion, 62.0% of
patients received the recommended treatment; these patients were more likely to be alive at 1 year
compared with those who did not receive the recommended treatment (P = 0.007). More of the patients
who followed recommendations underwent liver transplantation (25.6% versus 14.4%; P = 0.10).
Conclusions: There are patient-related as well as physician-related reasons for non-adherence to
recommendations. Non-adherence affects clinical outcomes and can be avoided in selected cases.
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Introduction
Hepatocellular carcinoma (HCC) is the fastest-growing cause of
cancer-related death in the USA.1 There are several explanations
for the rising burden of disease, including the natural history of
the national hepatitis C epidemic, the immigration of people from
endemic hepatitis B regions, increased implementation of HCC
screening protocols, the increasing prevalence of non-alcoholic
steatohepatitis, and the ageing of the population.
Fortunately, to meet the needs of the growing, complex popu-
lation with HCC, great strides have been achieved over the past
two decades and have resulted in excellent surgical and
locoregional as well as pharmacologic options. As a result, several
disciplines have a stake in the management of an HCC patient.
From his or her initial evaluation to confirmation of diagnosis and
treatment, the HCC patient is cared for by a combination of
internists, hepatologists, pathologists, radiologists (diagnostic and
interventional), surgeons and oncologists (medical and radia-
tion). To coordinate HCC treatment, the new standard of care
involves interdisciplinary collaboration initiated as multidiscipli-
nary tumour conferences (MTCs).
A wealth of data on the outcomes of HCC management have
been published in journals that cater to any of the aforementioned
disciplines. Issues include the primacy of liver transplantation for
HCC,2,3 resection versus ablation for small tumours,4 the impact
of Child–Turcotte–Pugh class on outcome,5 radiofrequency
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ablation (RFA) versus transarterial chemoembolization (TACE),6
and the treatment of very early HCC.7 Clearly, caring for patients
with HCC requires collaboration among the aggregate specialists.
The matching of the patient with HCC and the correct therapy
requires deliberation and multidisciplinary input. Accordingly,
the MTC is a good example of personalized medicine. The MTC
is also, in effect, a tool. Tools can be inefficient, misused
or misunderstood. Especially complex tools require pause for
re-evaluation. They can be crafted and improved. Tools should be
judged by their ability to satisfy their intended aims.
The primary aim of this retrospective analysis was to describe
the reasons for non-adherence to MTC management recommen-
dations. The secondary aim was to correlate adherence patterns
with clinical outcomes, particularly with respect to liver trans-
plantation. The present paper describes the 3.5-year experience of
a single referral centre in the MTC.
Materials and methods
Setting and patients
The Beth Israel Deaconess Medical Center (BIDMC) is a 649-bed
teaching hospital affiliated with Harvard Medical School and
located in Boston, Massachusetts. It is one of the main referral
centres for liver transplantation in New England. Within the
BIDMC liver centre, there is a liver tumour clinic that aims to
coordinate care among subspecialists in the treatment of patients
with both primary and metastatic tumours. An MTC is held
weekly to discuss patients with suspected or established HCC.
Attendees include five hepatologists, three oncologists, one radia-
tion oncologist, three interventional radiologists, one pathologist,
three surgeons, three radiologists, and five mid-level staff includ-
ing nurses, nurse practitioners and physician assistants. The goal
of this meeting is to construct an individualized diagnostic and
treatment plan for each of the patients discussed.
At every MTC, a designated team member, typically a nurse
practitioner or physician assistant, inserts a short summary of
each discussion into the BIDMC online medical records (OMR).
This documentation includes a pertinent history of the patient’s
underlying liver disease and tumour, completed diagnostic
studies, and any prior treatment. The recorder also includes rel-
evant changes that have occurred in the interim between meet-
ings, and a brief description of imaging reviewed during theMTC.
Lastly, the specific recommendations for each patient, such as
follow-up imaging [ultrasound, computed tomography (CT),
magnetic resonance imaging (MRI)] with a timeframe for com-
pletion, biopsy, RFA, TACE, cyberknife (CK), surgical resection,
systemic therapy and/or liver transplantation are documented.
The MTC recommendations are specific and therefore any devia-
tion is considered a discrepancy.
In this retrospective cohort study, data were collected for 137
patients diagnosed with cirrhosis and HCC whose cases were
presented to a first MTC discussion between January 2009 and
December 2010. The diagnosis of HCC was confirmed for every
patient according to National Comprehensive Cancer Network
guidelines using radiographic, biochemical and histologic find-
ings. The mean number of discussions per patient was three
(median: 2; mode: 2). The mean follow-up time from first discus-
sion until the primary outcome (death, transplantation, alive
without transplant at 15 July 2012, or loss from follow-up) was
16.7 months or 502 days. Patients were excluded from the study if
they did not have a confirmed diagnosis of HCC, if their first MTC
discussion was prior to 2009 or after 2010, or if there was insuf-
ficient documentation in the OMR (n = 2).
Database and data collection
A database was constructed using Microsoft Access to securely
store all collected information. A retrospective chart review was
performed to determine basic demographic information and
underlying liver disease in all patients who met the inclusion
criteria. Clinical characteristics as well as details of all MTC case
discussions were available through the hospital’s OMR. Each
MTC meeting prior to 15 July 2012 was reviewed as a separate
event. At every discussion, Child–Turcotte–Pugh status was deter-
mined. Prior treatments including liver-directed therapy (RFA,
TACE, CK), surgical resection, transplantation and systemic
therapy were noted. The MTC plan for observation, diagnostic
workup or preferred treatment was documented. In addition,
actual actions were identified, and whether or not they differed
from the original recommendations was noted. The primary out-
comes were death, transplantation, alive without transplant at 15
July 2012 and loss from follow-up. The date of a patient’s death
was confirmed using the Social Security Death Master File
(SSDMF). The date of liver transplantation was confirmed by
review of the hospital OMR.
Statistics
Information stored in Microsoft Access was exported to Microsoft
Excel for analysis. All data were kept in a firewall-secured server
and/or password-protected Microsoft Excel file (Version Info;
Microsoft Corp., Redmond, WA, USA). Data were analysed using
jmp sas Version 8 (SAS Institute, Inc., Cary, NC, USA). Data are
recorded as the median (days) or as percentages as noted in the
tables. Descriptive statistics included the mean and standard
deviation (SD) for normal distributions and the median and
range for non-normal distributions (e.g. distributions in which
the SD exceeded the mean). Means were compared using the
Wilcoxon rank sum method and proportions were compared
using Fisher’s exact method.
Results
Patient characteristics
A total of 137 unique patients met the study inclusion criteria
(Fig. 1). Patients were verified as having a diagnosis of HCC and
cirrhosis on manual chart review. Table 1 summarizes the baseline
characteristics of all included patients categorized according to
the Child–Pugh class designated at the initial discussion. In two
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patients, Child–Pugh class could not be determined based on the
limited information available in the OMR. The median age of the
patients was 60 years. The majority of patients were male (n = 116,
84.7%) andWhite (n = 99, 72.3%). The most common aetiologies
of underlying liver disease were hepatitis C (n = 85, 62.0%),
alcohol consumption (n = 45, 32.8%), and hepatitis B (n = 17,
12.4%). Some patients had multiple aetiologies of cirrhosis (n =
28, 20.4%). Prior HCC treatment had been delivered in 36
patients; the most common treatment prior to the first MTC
discussion was RFA (n = 16, 11.7%), followed by TACE (n = 10,
7.3%) and resection (n = 10, 7.3%).
Survival after first treatment
Treatment recommendations after the first MTC, the first treat-
ment completed, and survival data are summarized in Table 2.
Thirty-six patients (26.3%) had received treatment prior to their
first MTC presentation. Patients with no prior treatment survived
longer [mean: 603 days, 95% confidence interval (CI) 395–673
days] than those with prior treatment (mean: 368 days, 95% CI
231–471 days), although the difference did not reach statistical
significance (P = 0.248). In two-thirds of patients, at least one
treatment was recommended at the first discussion. A total of 92
patients (67.2%) received at least one treatment after their initial
MTC presentation. Overall, patients who received at least one
treatment after their first MTC were more likely to be alive at 1
year after their first treatment than those without treatment
(58.7% versus 39.5%; P = 0.043). Notably, patients in whom liver
transplantation represented the first treatment achieved 100%
survival at 1 year.
Liver transplantation and the MTC
Of the 137 patients discussed, 43 (31.4%) were listed for liver
transplant. A total of 23 patients actually underwent liver trans-
plantation, representing 53.5% of patients listed and 16.8% of all
patients discussed. Thirty-two of the 43 patients listed for trans-
plant were listed after their first MTC presentation, and 19 of these
patients (59.4%) underwent liver transplantation. Time from first
discussion to listing and time from listing to transplantation are
summarized in Table 3. None of the 19 transplanted patients had
received any treatment prior to their first MTC presentation.
However, 13 patients did undergo at least one liver-directed
treatment (RFA, n = 12; TACE, n = 4; CK, n = 1) prior to trans-
plantation. For one patient, complications related to the MTC-
recommended procedure led to transplantation. In this patient,
surgical resection was performed and the postoperative course
was complicated by liver failure, resulting in liver transplantation.
Remarkably, all of the patients who underwent transplantation
were still alive at the conclusion of the study.
Of the remaining 13 patients listed for liver transplantation
after their first MTC presentation, eight did not undergo trans-
plantation for the following reasons: death (n = 2); progression of
disease outside the Milan criteria (n = 2); deciding against liver
transplantation (n = 1), listed and awaiting transplant (n = 3). The
reasons why the remaining five patients did not undergo liver
transplantation were multifactorial and related to periods of deac-
tivation and subsequent delisting for substance abuse, non-
adherence, worsening of clinical status, progression of HCC,
patient choice or a new additional cancer diagnosis.
Concordance with MTC recommendations
A total of 419 discussions of 137 distinct patients took place
during the period under study. The recommendations made in
MTCs were not followed after 145 discussions of 90 individual
patients. Table 4 summarizes this information. There were
patient-related reasons for discordance, which included failure to
attend for follow-up (n = 24, 16.6%), clinical deterioration (n =
19, 13.1%) and patient preferences (n = 13, 9.0%). Physician-
related reasons for deviations from MTC recommendations
included the preference of the treating physician (n = 43, 29.7%)
and the discovery that the patient was not a candidate for the
recommended treatment (n = 37, 25.5%). The top three reasons
why these 37 patients were considered not to represent appropri-
ate candidates were that the recommendation was inappropriate
for the stage of disease or was contraindicated (n = 18, 48.6%), the
intervention was not technically feasible (n = 12, 32.4%), and new
clinical information became available and led to a change in the
initial MTC plan (n = 7, 18.9%).
Table 5 summarizes the frequencies with which certain recom-
mendations were not followed. Locoregional procedures as a
group, including RFA, TACE and CK, were less likely to be fol-
lowed. Radiofrequency ablation accounted for half of these
locoregional procedures. In only seven cases was the recommen-
dation changed from one locoregional procedure to another (i.e.
Is patient cirrhotic?
All patients
discussed at MTC
between Jan 2009
and Dec 2010
First discussion?
Lesion confirmed
HCC?
137 patients
identified with
cirrhosis and HCC
No
No
No
Yes
Yes
Yes
Figure 1 Patient selection for the present study according to date of
first presentation at a multidisciplinary tumour conference (MTC) and
diagnosis of hepatocellular carcinoma (HCC) and cirrhosis
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from RFA to TACE) or an additional locoregional procedure was
performed in addition to that originally recommended.
A comparison of those patients in whom all MTC recommen-
dations were followed with those in whom at least one recommen-
dation was not followed shows rates of survival to 1 year after the
first MTC presentation of 61.7% and 56.7%, respectively (P =
0.29). Although the difference is not statistically significant, there
were trends towards improved survival from first MTC presenta-
tion in patients whose treatment adhered to recommendations
compared with those whose treatment did not by Child–Pugh
class. In patients with Child–Pugh class A status, mean ± SD
survival was 610.7 ± 407.6 days in those who adhered and 523.5 ±
340.5 days in those who did not (P = 0.33). In patients with
Child–Pugh class B status, mean ± SD survival was 519.6 ± 390.4
days in those who adhered and 474.7 ± 391.7 days in those who
did not (P = 0.74). In patients with Child–Pugh class C status,
mean ± SD survival was 467.2 ± 542.3 days in those who adhered
and 302.7 ± 268.1 days in those who did not (P = 0.37). More
patients who followed recommendations underwent liver trans-
plantation (25.6% and 14.4%, respectively; P = 0.10).
Table 1 Characteristics of patients with cirrhosis and hepatocellular carcinoma at first presentation at a multidisciplinary tumour conference
Child–Pugh status Total
Class A Class B Class C Unknown
Patients, n (%) 81 (59.1%) 34 (24.8%) 20 (14.6%) 2 (1.5%) 137
Age, years, median 62.0 58.5 60.0 63.5 60.0
Sex, n (%)
Male 68 (84.0%) 29 (85.3%) 17 (85.0%) 2 116 (84.7%)
Female 13 (16.0%) 5 (14.7%) 3 (15.0%) 0 21 (15.3%)
Race, n (%)
White 48 (59.3%) 31 (91.2%) 20 (100%) 0 99 (72.3%)
African-American 8 (9.9%) 1 (2.9%) 0 0 9 (6.6%)
Hispanic 8 (9.9%) 0 0 0 8 (5.8%)
East Asian 9 (11.1%) 1 (2.9%) 0 0 10 (7.3%)
Southeast Asian 3 (3.7%) 0 0 0 3 (2.2%)
Unknown 5 (6.2%) 1 (2.9%) 0 2 (100%) 8 (5.8%)
Aetiology of liver diseaseb, n (%)
Hepatitis B 13 (16.0%) 3 (8.8%) 1 (5.0%) 0 17 (12.4%)
Hepatitis C 48 (59.3%) 24 (70.6%) 13 (65.0%) 0 85 (62.0%)
Alcohol 18 (22.2%) 16 (47.1%) 11 (55.0%) 0 45 (32.8%)
NASH 6 (7.4%) 3 (8.8%) 0 1 (50.0%) 10 (7.3%)
Haemochromatosis 3 (3.7%) 0 1 (5.0%) 0 4 (2.9%)
Other/unknown 3 (3.7%) 0 1a (5.0%) 1 (50.0%) 5 (3.6%)
Multiple aetiologies, n (%)
HBV + HCV 1 (1.2%) 0 0 0 1 (0.7%)
HCV + alcohol 7 (8.6%) 12 (35.3%) 5 (25.0%) 0 24 (17.5%)
HBV + HCV + alcohol 0 0 1 (5.0%) 0 1 (0.7%)
HCV + haemochromatosis 2 (2.5%) 0 0 0 2 (1.5%)
Prior treatmentb, n (%)
All patients 24 (29.6%) 6 (17.6%) 5 (25.0%) 1 (50.0%) 36 (26.3%)
RFA 12 (14.8%) 2 (5.9%) 2 (10.0%) 0 16 (11.7%)
TACE 8 (9.9%) 0 1 (5.0%) 1 (50.0%) 10 (7.3%)
CK 3 (3.7%) 0 0 0 3 (2.2%)
Resection 8 (9.9%) 2 (5.9%) 0 0 10 (7.3%)
Systemic treatment 1 (1.2%) 2 (5.9%) 2 (10.0%) 0 5 (3.6%)
aSchistosomiasis.
bAs a result of multiple aetiologies or treatments, sum may be greater than 100%.
NASH, non-alcoholic steatohepatitis; HBV, hepatitis B virus; HCV, hepatitis C virus; RFA, radiofrequency ablation; TACE, transarterial
chemoembolization; CK, cyberknife.
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Discussion
Hepatocellular carcinoma is the third most common cause of
cancer-related death and the most common cause of death among
patients with cirrhosis.8,9 In patients with HCC and cirrhosis, liver
transplantation represents the most effective treatment option.10
Because the management of patients with HCC is complex, a
multidisciplinary approach is crucial.11,12 Increased survival in
patients with cirrhosis who develop HCC has been demonstrated
in recent years.13 This is likely to in part reflect the imposition of
standardized screening guidelines, advances in therapy, and
perhaps the tool of interdisciplinary collaboration. As with all
Table 2 First treatment after first presentation at a multidisciplinary tumour conference (MTC) and survival
Recommended
treatment, na
Completed
treatment,
n (%)
Time from MTC
to treatment,
days, median
Survival at 1
year after MTC
n (%)c
Survival at 1 year
after first treatment
n (%)c,d
Liver-directedb 57 66 (48.2%) 49 46 (69.7%) 44 (66.7%)
Resection 15 9 (6.6%) 28 5 (55.6%) 4 (44.4%)
Transplant 18 8 (5.8%) 398 8 (100%) 8 (100%)
Systemic treatment 12 9 (6.6%) 32 5 (55.6%) 4 (44.4%)
No treatment 47 45 (32.8%) n/a 16 (35.6%) NA
Any treatment 88 92 (67.2%) 49 64 (69.6%) 60 (65.2%)
aSum of recommended treatments may be greater than 100% as a result of multiple treatment recommendations.
bLiver-directed therapy includes radiofrequency ablation, transarterial chemoembolization, cyberknife.
cPercentage within treatment group.
dAssumes those with treatment within 1 year of study end date are alive.
NA, not applicable.
Table 3 Data for patients submitted to transplantation according to multidisciplinary tumour conference (MTC) recommendations
Patients listed
after first
MTC, n
Time from first
MTC to listing,
days, median
Patients
successfully
transplanted, n
Time from listing
to transplant,
days, median
Child–Pugh class A 18 134 8 98
Child–Pugh class B 11 83 10 156
Child–Pugh class C 3 56 1 350
Total 32 89.5 19 142
Table 4 Reasons why multidisciplinary tumour conference recommendations were not followed
Patient-related reasons Physician-related reasons Otherc Totalb n (%)
Patient did not
follow up
Patient
deteriorated
Patient
preference
Patient not
a candidate
Treating physician
preferred alternative
Child–Pugh class A, n 14 4 6 20 24 2 70 (48.3%)
Child–Pugh class B, n 5 4 3 12 12 3 39 (26.9%)
Child–Pugh class C, n 4 10 4 5 7 4 34 (23.4%)
Child–Pugh class unknown, n 1 1 0 0 0 0 2 (1.4%)
Totala, n (%) 24 (16.6%) 19 (13.1%) 13 (9.0%) 37 (25.5%) 43 (29.7%) 9 (6.2%) 145
aPercentage within reason recommendation not followed.
bPercentage within Child–Pugh class.
cChart review does not show a clear reason why the recommendation was not followed.
Table 5 Recommendations not followed
Recommendation not
followed
n (%)a
Imaging 25 (17.2%)
Biopsy 31 (21.4%)
Resection 9 (6.2%)
Transplant 9 (6.2%)
Radiofrequency ablation 31 (21.4%)
Transarterial chemoembolization 15 (10.3%)
Cyberknife 19 (13.1%)
Systemic therapy 16 (11.0%)
Other 8 (5.5%)
aBecause of multiple recommendations per multidisciplinary tumour
conference, sum may be greater than 100%.
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therapies for HCC, the function of an MTC requires examina-
tion in order to maximize patient benefit and to address any
shortcomings.
In this study, the function of a multidisciplinary HCC tumour
conference at a tertiary referral centre was examined and the
outcomes of patients with HCC and cirrhosis were described. The
principle finding of the current study is that in two-thirds of all
patients discussed, at least one MTC recommendation was not
followed. In fact, one-third of all MTC discussions included rec-
ommendations that were not adhered to, a statistic much higher
than expected. Secondly, the present study found that there were
both patient and physician explanations for the discrepancy, and
that locoregional procedures as a group were least likely to be
followed. Thirdly, the study showed clinical trends towards
improved survival, and an increased likelihood of transplantation
when MTC recommendations were followed. This study suggests
that an informed, multidisciplinary approach to patients with
cirrhosis and HCC is valuable. Future studies with larger sample
sizes may help to disprove the null hypothesis.
Patients with no prior treatment survived longer than patients
who were treated before their first MTC presentation. There were
many reasons for this difference in the present study. Firstly,
patients with prior treatment had been diagnosed with HCC for
longer than patients with no prior treatment, and therefore their
disease may have been more advanced at the time of their first
MTC. Secondly, patients with prior treatment had often been
referred from outside institutions in order to obtain a second
opinion in relation to liver transplantation and hence represented
a selected group of medically complex individuals. Lastly, patients
with prior treatments were likely to have been subject to treatment
decisions made outwith a multidisciplinary setting, which may
have contributed to a poorer outcome.
Adherence to MTC decisions is a complex issue. Each patient
has unique characteristics, and decisions on observation, addi-
tional diagnostics and treatment modalities are not straight-
forward. Despite initial agreement among specialists at the weekly
MTCmeetings, many reasons for diverting from the management
plan may have arisen. There were often unforeseen aspects of a
patient’s clinical trajectory or missing data that led to a change of
plan. Patient-related factors that affect adherence, such as personal
choice, failure to attend for follow-up and clinical decline, may be
unavoidable in some cases but are clearly important areas for
improvements in education and patient compliance. Physician-
related reasons for non-adherence are also notable and may rep-
resent areas for quality improvement. Two of the reasons for
discordance between recommendations and actual actions
referred to the recommendation being unfeasible and the recom-
mendation being inappropriate or contraindicated for the stage of
disease. Whether these problems could have been prevented is
speculative but conceivable.
What might account for the discrepancy? Is it an endogenous
risk factor such as incomplete knowledge of the clinical aspects of
the case or of scientific (i.e. evidence-based) standards? Should
there be a standard of clinical data, such as Child–Pugh class or
α-fetoprotein trend, to enable the better presentation of a case?
Should a citation of evidence-based practice be recorded with
each decision made? Is there adequate representation at MTC
meetings of treatment providers? Are the laboratory and imaging
data for outside referrals presented prior to the patient’s first visit
with a new provider? The introduction of new rules that address
these concerns might perhaps help to decrease the discrepancy.
However, it may be that there are exogenous reasons for discrep-
ancy, such as that too many case discussions take place on a given
day and thus the time and attention given to each are insufficient.
A risk factor like this is easily remedied. The design of this study
does not lend itself to answering all of these queries.
An ‘ideal’ MTC is one that meets regularly to individually
review each patient’s case in order to determine a personalized
diagnostic and treatment plan. There is a designated chair and a
coordinator, who is responsible for conference management. Rep-
resentatives from each specialty, including hepatology, transplant
surgery, medical oncology, radiation oncology, radiology,
interventional radiology and nursing, are present at each meeting
to provide a complete range of expert opinion about the disease
process.Attendance should bemandatory for all clinicians directly
involved in the care of the patient being presented. Input should
be encouraged from all members of the team, and the outcome of
eachmeeting should be clearly documented in the medical record.
This study brings to attention some imperfections of the MTC.
In the present institution, MTC attendance is not perfect and the
treating clinicianmay not be present at all MTCmeetings.Outside
referrals are sometimes presented at the MTC before the patient
has been seen in clinic, and thus the group is not aware of the
patient’s functional status or preferences, knowledge of which is
essential to making an informed recommendation. In this study,
recommendations for locoregional procedures were least likely to
be followed. The interventional radiologist performing the pro-
cedure may not be the physician who was present at the MTC
meeting. Policies that mandate attendance by treating providers,
discussion only after initial patient evaluation, and scheduling of
locoregional treatment by the interventional radiologist present
for the MTC discussion may limit this discordance. In situations
in which the MTC recommendation is found to be unfeasible or
inappropriate, the treating clinician often determines the next
appropriate treatment or waits until the patient’s status improves
to provide the recommended treatment. Strict rules should be
created to ensure that patients under these circumstances are rep-
resented in a timely fashion at the next MTC meeting. This inter-
vention would also serve as quality improvement for the MTC so
that the group can be made more aware of these situations.
The role of the MTC in liver transplantation is also important
because transplantation represents the best cure for patients with
cirrhosis andHCC. By having an instrument such as theMTC that
functions to bring together HCC specialists, newly diagnosed
cases of HCC can be discussed in a timely manner, and
suggestions regarding appropriate follow-up, further testing and
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treatment can be made. Furthermore, the coordination of the care
necessary to complete a transplant workup of those patients who
domeet the criteria can be put into place promptly to enable these
patients to be listed. Once a patent has been listed for transplant,
liver-directed bridging therapies are important to consider, espe-
cially in patients who are expected to experience a prolonged wait
time.14–17 The MTC represents an opportunity to review each case
routinely with all of the specialists involved in order to develop the
best personalized treatment plan.When all of these variables work
together, patients should do better, but external validation from
other MTC groups is needed.
The present study has some limitations. Firstly, it represents a
single-centre experience with a regional and small population,
which may diminish the generalizability of the results. Future
studies should combine data from multiple referral centres. This
studymay also be subject to self-selection bias in that patients who
are more motivated are more likely to follow MTC recommenda-
tions and do better. In addition, this study is retrospective and
data collection was limited by the documentation available in the
OMR.
Multidisciplinary collaboration among physicians in the man-
agement of patients with HCC has been previously shown to
improve patient survival.18 The present data suggest an insignifi-
cant trend towards improved survival and transplantation
when management recommendations are carried out. Larger
multicentre studies examining the function of an MTC are
needed. The defining of physician-related reasons for non-
adherence to MTC recommendations will make it possible to
work towards developing and implementing strategies to mini-
mize discordance and impact on patient survival.
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